About
Technology
Issues
FAQ
Links
Official Page
A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.